Literature DB >> 19497413

The selenium analog of the chemopreventive compound S,S'-(1,4-phenylenebis[1,2-ethanediyl])bisisothiourea is a remarkable inducer of apoptosis and inhibitor of cell growth in human non-small cell lung cancer.

Arunangshu Das1, James Bortner, Dhimant Desai, Shantu Amin, Karam El-Bayoumy.   

Abstract

Lung cancer continues to be the leading cause of cancer deaths throughout the world and conventional therapy remains largely unsuccessful. Although, chemoprevention is a plausible alternative approach to curb the lung cancer epidemic, clinically there are no effective chemopreventive agents. Thus, development of novel compounds that can target cellular and molecular pathways involved in the multistep carcinogenesis process is urgently needed. Previous studies have suggested that substitution of sulfur by selenium in established cancer chemopreventive agents may result in more effective analogs. Thus in the present study we selected the chemopreventive agent S,S'-(1,4-phenylenebis[1,2-ethanediyl])bisisothiourea (PBIT), also known to inhibit inducible nitric oxide synthase (iNOS), synthesized its selenium analog (Se-PBIT) and compared both compounds in preclinical model systems using non-small cell lung cancer (NSCLC) cell lines (NCI-H460 and A549); NSCLC is the most common histologic type of all lung cancer cases. Se-PBIT was found to be superior to PBIT as an inducer of apoptosis and inhibitor of cell growth. Se-PBIT arrested cell cycles at G1 and G2-M stage in both A549 and H460 cell lines. Although both compounds are weakly but equally effective inhibitors of iNOS protein expression and activity, only Se-PBIT significantly enhanced the levels of p53, p38, p27 and p21 protein expression, reduced levels of phospholipase A2 (PLA2) but had no effect on cyclooxygenase-2 (COX-2) protein levels; such molecular targets are involved in cell growth inhibition, induction of apoptosis and cell cycle regulation. The results indicate that Se-PBIT altered molecular targets that are involved in the development of human lung cancer. Although, the mechanisms that can fully account for these effects remain to be determined, the results are encouraging to further evaluate the chemopreventive efficacy of Se-PBIT against the development of NSCLC in a well-defined animal model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19497413      PMCID: PMC3690934          DOI: 10.1016/j.cbi.2009.03.003

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  40 in total

1.  Arsenite induces apoptosis in hepatocytes through an enhancement of the activation of Jun N-terminal kinase and p38 mitogen-activated protein kinase caused by partial hepatectomy.

Authors:  Tomoko Suzuki; Ikuyo Tsukamoto
Journal:  Toxicol Lett       Date:  2006-05-12       Impact factor: 4.372

2.  Involvement of p38 mitogen-activated protein kinase in the cell growth inhibition by sodium arsenite.

Authors:  Ja-Young Kim; Jung-A Choi; Tae-Hwan Kim; Young-Do Yoo; Jong-Il Kim; Yong J Lee; Seong-Yul Yoo; Chul-Koo Cho; Yun-Sil Lee; Su-Jae Lee
Journal:  J Cell Physiol       Date:  2002-01       Impact factor: 6.384

3.  Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer.

Authors:  Ioannis S Pateras; Kalliopi Apostolopoulou; Marilena Koutsami; Kostas Evangelou; Petros Tsantoulis; Triantafillos Liloglou; Giorgos Nikolaidis; Fragiska Sigala; Christos Kittas; John K Field; Athanassios Kotsinas; Vassilis G Gorgoulis
Journal:  Int J Cancer       Date:  2006-12-01       Impact factor: 7.396

4.  EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups.

Authors:  N van Zandwijk; O Dalesio; U Pastorino; N de Vries; H van Tinteren
Journal:  J Natl Cancer Inst       Date:  2000-06-21       Impact factor: 13.506

Review 5.  Selenium and anticarcinogenesis: underlying mechanisms.

Authors:  Matthew I Jackson; Gerald F Combs
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2008-11       Impact factor: 4.294

6.  Increased inducible nitric oxide synthase in lung carcinoma of smokers.

Authors:  George G Chen; Tak Wai Lee; Hu Xu; Johnson H Y Yip; Mingyue Li; Tony S K Mok; Anthony P C Yim
Journal:  Cancer       Date:  2008-01-15       Impact factor: 6.860

7.  PBISe, a novel selenium-containing drug for the treatment of malignant melanoma.

Authors:  SubbaRao V Madhunapantula; Dhimant Desai; Arati Sharma; Sung Jin Huh; Shantu Amin; Gavin P Robertson
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

8.  Selenium activates p53 and p38 pathways and induces caspase-independent cell death in cervical cancer cells.

Authors:  E Rudolf; K Rudolf; M Cervinka
Journal:  Cell Biol Toxicol       Date:  2007-07-03       Impact factor: 6.691

9.  Differential activity of NO synthase inhibitors as chemopreventive agents in a primary rat tracheal epithelial cell transformation system.

Authors:  Sheela Sharma; Betty P Wilkinson; Pu Gao; Vernon E Steele
Journal:  Neoplasia       Date:  2002 Jul-Aug       Impact factor: 5.715

10.  Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite.

Authors:  Guang-xun Li; Hyo-Jeong Lee; Zhe Wang; Hongbo Hu; Joshua D Liao; Jennifer C Watts; Gerald F Combs; Junxuan Lü
Journal:  Carcinogenesis       Date:  2008-02-28       Impact factor: 4.944

View more
  8 in total

1.  Antileishmanial activity of imidothiocarbamates and imidoselenocarbamates.

Authors:  David Moreno; Daniel Plano; Ylenia Baquedano; Antonio Jiménez-Ruiz; Juan Antonio Palop; Carmen Sanmartín
Journal:  Parasitol Res       Date:  2010-10-05       Impact factor: 2.289

2.  Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma.

Authors:  Raghavendra Gowda; Subbarao V Madhunapantula; Dhimant Desai; Shantu Amin; Gavin P Robertson
Journal:  Mol Cancer Ther       Date:  2012-10-30       Impact factor: 6.261

3.  Asperolide A, a marine-derived tetranorditerpenoid, induces G2/M arrest in human NCI-H460 lung carcinoma cells, is mediated by p53-p21 stabilization and modulated by Ras/Raf/MEK/ERK signaling pathway.

Authors:  Cuiting Lv; Wenxia Sun; Haofen Sun; Shanjian Wei; Ruohua Chen; Bingui Wang; Caiguo Huang
Journal:  Mar Drugs       Date:  2013-01-29       Impact factor: 5.118

4.  PVM/MA-shelled selol nanocapsules promote cell cycle arrest in A549 lung adenocarcinoma cells.

Authors:  Ludmilla Regina de Souza; Luis Alexandre Muehlmann; Mayara Simonelly Costa Dos Santos; Rayane Ganassin; Rosana Simón-Vázquez; Graziella Anselmo Joanitti; Ewa Mosiniewicz-Szablewska; Piotr Suchocki; Paulo César Morais; África González-Fernández; Ricardo Bentes Azevedo; Sônia Nair Báo
Journal:  J Nanobiotechnology       Date:  2014-08-23       Impact factor: 10.435

Review 5.  Selenium compounds, apoptosis and other types of cell death: an overview for cancer therapy.

Authors:  Carmen Sanmartín; Daniel Plano; Arun K Sharma; Juan Antonio Palop
Journal:  Int J Mol Sci       Date:  2012-08-02       Impact factor: 6.208

6.  Combination of fenretinide and selenite inhibits proliferation and induces apoptosis in ovarian cancer cells.

Authors:  Jie Liu; Jia Li; Jian-Fang Zhang; Xiao-Yan Xin
Journal:  Int J Mol Sci       Date:  2013-11-04       Impact factor: 5.923

7.  A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer.

Authors:  Hephzibah Rani S Tagaram; Dhimant Desai; Guangfu Li; Dai Liu; C Bart Rountree; Kavitha Gowda; Arthur Berg; Shantu Amin; Kevin F Staveley-O'Carroll; Eric T Kimchi
Journal:  Pharmaceuticals (Basel)       Date:  2016-03-24

8.  Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine.

Authors:  David J Wooten; Indu Sinha; Raghu Sinha
Journal:  Biomedicines       Date:  2022-01-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.